Clinical trials: Dysthyroid Orbitopathy
Thyroid Eye Disease
B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease
Thyroid eye disease (TED) is an autoimmune inflammation of the orbital tissues that develops in up to 50% of patients with Graves' disease.
- Trial name
- BetTeRTED (NCT02316691)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pittsburgh
Thyroid Eye Disease
Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.
- Trial name
- TED (NCT05683496)
- Testing
- lonigutamab
- Where
- 11 sites in United States, Australia
- Volunteers
- 31 people
- Sponsor
- ACELYRIN Inc.
Graves Ophthalmopathy
T and B Cells in Graves' Orbitopathy
Graves orbitopathy (GO) is an inflammatory eye disease associated in 95% of patients with Graves' hyperthyroidism (GH), in ~3-4% with hypothyroid autoimmune thyroiditis, and in ~1-2% with thyroid autoimmunity in the absence of…
- Trial name
- LYMPHGO (NCT03195296)
- Testing
- No intervention
- Volunteers
- 20 people
- Sponsor
- University of Pisa
Thyroid Associated Ophthalmopathy
Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial)
Thyroid ophthalmopathy, also known as thyroid eye disease or Graves' ophthalmopathy, is a condition characterized by inflammation and swelling of the tissues around the eyes, often accompanied by protrusion of the eyeballs.
- Trial name
- NCT06392906
- Testing
- Short course radiation therapy, Standard course radiation therapy
- Where
- Thailand
- Volunteers
- 68 people
- Sponsor
- Janjira Petsuksiri
Thyroid Eye Disease (TED)
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
- Trial name
- NCT06812325
- Testing
- VRDN-003
- Where
- 64 sites in United States, France and 5 more
- Volunteers
- 320 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease
A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease
This trial will evaluate the effects of Lu AG22515 in adult men and women with moderate-to-severe thyroid eye disease (TED). TED is an autoimmune condition closely related to Graves' Disease.
- Trial name
- NCT06557850
- Testing
- Lu AG22515
- Where
- 6 sites in Bosnia and Herzegovina, Bulgaria and 1 more
- Volunteers
- 20 people
- Sponsor
- H. Lundbeck A/S